MA39172A1 - Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines - Google Patents

Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines

Info

Publication number
MA39172A1
MA39172A1 MA39172A MA39172A MA39172A1 MA 39172 A1 MA39172 A1 MA 39172A1 MA 39172 A MA39172 A MA 39172A MA 39172 A MA39172 A MA 39172A MA 39172 A1 MA39172 A1 MA 39172A1
Authority
MA
Morocco
Prior art keywords
inhibitors
bromodomaine
bicyclic derivatives
heterocyclic bicyclic
heterocyclic
Prior art date
Application number
MA39172A
Other languages
English (en)
Other versions
MA39172B1 (fr
Inventor
Susanta Samajdar
Chandrasekhar Abbineni
Sanjita Sasmal
Subramanya Hosahalli
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MA39172A1 publication Critical patent/MA39172A1/fr
Publication of MA39172B1 publication Critical patent/MA39172B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des dérivés bicycliques hétérocycliques de formule (i), qui peuvent être thérapeutiquement utiles, plus particulièrement comme inhibiteurs de bromodomaines ; (i), dans laquelle r
MA39172A 2014-01-09 2015-01-06 Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines MA39172B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN125CH2014 2014-01-09
PCT/IB2015/050090 WO2015104653A1 (fr) 2014-01-09 2015-01-06 Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines

Publications (2)

Publication Number Publication Date
MA39172A1 true MA39172A1 (fr) 2018-04-30
MA39172B1 MA39172B1 (fr) 2018-10-31

Family

ID=52462967

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39172A MA39172B1 (fr) 2014-01-09 2015-01-06 Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines

Country Status (30)

Country Link
US (2) US10077259B2 (fr)
EP (1) EP3092227B1 (fr)
JP (1) JP6480944B2 (fr)
KR (1) KR102394518B1 (fr)
CN (1) CN106061966B (fr)
AU (1) AU2015205339B2 (fr)
BR (1) BR112016015311B1 (fr)
CA (1) CA2934788C (fr)
CL (1) CL2016001737A1 (fr)
CY (1) CY1122046T1 (fr)
DK (1) DK3092227T3 (fr)
EA (1) EA029224B1 (fr)
ES (1) ES2687497T3 (fr)
HR (1) HRP20181650T1 (fr)
HU (1) HUE041546T2 (fr)
IL (1) IL246140B (fr)
LT (1) LT3092227T (fr)
MA (1) MA39172B1 (fr)
MX (1) MX2016009052A (fr)
MY (1) MY190835A (fr)
PE (1) PE20161021A1 (fr)
PH (1) PH12016501355A1 (fr)
PL (1) PL3092227T3 (fr)
PT (1) PT3092227T (fr)
RS (1) RS57586B1 (fr)
SA (1) SA516371448B1 (fr)
SG (1) SG11201604916YA (fr)
SI (1) SI3092227T1 (fr)
UA (1) UA117165C2 (fr)
WO (1) WO2015104653A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201707487VA (en) 2013-03-15 2017-10-30 Incyte Corp Tricyclic heterocycles as bet protein inhibitors
WO2015095492A1 (fr) 2013-12-19 2015-06-25 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs des protéines bet
SG11201608843TA (en) 2014-04-23 2016-11-29 Incyte Corp 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
WO2016044130A1 (fr) 2014-09-15 2016-03-24 Incyte Corporation Hétérocycles tricycliques utilisés en tant qu'inhibiteurs des protéines bet
WO2017001733A1 (fr) * 2015-07-02 2017-01-05 Orion Corporation Dérivés d'hétérocycles bicycliques comme inhibiteurs de bromodomaines
KR20180039117A (ko) 2015-08-11 2018-04-17 네오메드 인스티튜트 아릴-치환된 디히드로퀴놀리논, 그의 제조법 및 제약으로서의 그의 용도
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
EP3334719B1 (fr) 2015-08-12 2021-09-15 Neomed Institute Benzimidazoles substitués, préparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques
WO2017066876A1 (fr) 2015-10-21 2017-04-27 Neomed Institute Imidazopyridines substituées, leur préparation et leur utilisation comme médicaments
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN105198871A (zh) * 2015-11-06 2015-12-30 中国药科大学 一类喹喔啉酮类化合物及其制备方法和用途
WO2017127930A1 (fr) 2016-01-28 2017-08-03 Neomed Institute [1,2,4]triazolo[4,3-a]pyridines substituées, leur préparation et leur utilisation comme médicaments
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
IL263824B2 (en) 2016-06-20 2023-10-01 Incyte Corp Crystals in solid form in the presence of an inhibitor
JP2020503312A (ja) 2016-12-22 2020-01-30 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 置換１，２，４−チアジアゾリルピロロンおよび１，２，４−チアジアゾリルヒダントイン、ならびにその塩、ならびにその除草剤としての使用
BR112019012567A2 (pt) 2016-12-22 2019-11-26 Bayer Ag azolilpirrolonas e azolil-hidantoínas substituídas e sais das mesmas e uso das mesmas como substâncias ativas herbicidas
WO2018161876A1 (fr) * 2017-03-08 2018-09-13 中国科学院上海药物研究所 Inhibiteur de protéine de reconnaissance de bromodomaine dihydroquinoxaline, son procédé de préparation et son utilisation
JP2020516672A (ja) 2017-04-18 2020-06-11 セルジーン クオンティセル リサーチ，インク． 治療用化合物
CN110092782B (zh) * 2018-01-30 2022-10-21 中国科学院广州生物医药与健康研究院 一种苯并六元氮杂环化合物及其制备方法和应用
CN110960528A (zh) * 2018-09-30 2020-04-07 四川大学 Ar和bet双重抑制剂及其用途
AU2019372121A1 (en) 2018-10-30 2021-05-27 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
CA3132934A1 (fr) 2019-04-11 2020-10-15 Eila Luukkonen Forme cristalline d'un inhibiteur bet et sa fabrication
BR112021026668A2 (pt) 2019-07-02 2022-02-15 Nuvation Bio Inc Compostos heterocíclicos como inibidores de bet
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR102600176B1 (ko) * 2021-10-18 2023-11-10 주식회사 사피엔스바이오 신규한 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10259176A (ja) * 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
US7777038B2 (en) * 2004-09-28 2010-08-17 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound
MY144974A (en) * 2005-06-14 2011-11-30 Eisai R&D Man Co Ltd 1,2-di(cyclic) substituted benzene derivatives
JP5191155B2 (ja) * 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
TW200918058A (en) * 2007-08-31 2009-05-01 Organon Nv TSH receptor antagonizing tetrahydroquinoline compounds
ES2382701T3 (es) * 2007-09-21 2012-06-12 Janssen Pharmaceutica, N.V. Inhibidores de la interacción entre MDM2 y p53
WO2009084693A1 (fr) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation Agent antitumoral
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2638014B1 (fr) * 2010-11-08 2017-01-04 Lycera Corporation Tétrahydroquinolines et composés bicycliques associés n-sulphonylées pour l'inhibition de l'activité rorgamma et le traitement de maladies
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (fr) * 2011-08-22 2013-02-28 Pfizer Inc. Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine
WO2013159095A1 (fr) * 2012-04-20 2013-10-24 Anderson Gaweco Modulateurs de ror et leurs utilisations
US9447069B2 (en) * 2012-04-30 2016-09-20 Innov17 Llc ROR modulators and their uses
KR20150135359A (ko) * 2013-03-14 2015-12-02 컨버진 엘엘씨 브로모도메인-함유 단백질의 억제를 위한 방법 및 조성물
US9199988B2 (en) * 2013-03-27 2015-12-01 Boehringer Ingelheim International Gmbh Dihydroquinazolinone analogues

Also Published As

Publication number Publication date
BR112016015311A2 (fr) 2017-08-08
AU2015205339B2 (en) 2018-07-05
LT3092227T (lt) 2018-08-10
US20180339982A1 (en) 2018-11-29
CL2016001737A1 (es) 2017-02-03
PT3092227T (pt) 2018-10-24
KR102394518B1 (ko) 2022-05-06
UA117165C2 (uk) 2018-06-25
EA201691404A1 (ru) 2016-10-31
PH12016501355B1 (en) 2017-02-06
IL246140B (en) 2019-09-26
WO2015104653A1 (fr) 2015-07-16
HUE041546T2 (hu) 2019-05-28
PE20161021A1 (es) 2016-11-09
US10077259B2 (en) 2018-09-18
CN106061966A (zh) 2016-10-26
PH12016501355A1 (en) 2017-02-06
EA029224B1 (ru) 2018-02-28
HRP20181650T1 (hr) 2018-12-14
RS57586B1 (sr) 2018-11-30
SG11201604916YA (en) 2016-07-28
CY1122046T1 (el) 2020-07-31
SI3092227T1 (sl) 2018-10-30
EP3092227A1 (fr) 2016-11-16
JP6480944B2 (ja) 2019-03-13
CA2934788C (fr) 2021-12-07
IL246140A0 (en) 2016-08-02
CN106061966B (zh) 2018-12-07
DK3092227T3 (en) 2018-09-03
CA2934788A1 (fr) 2015-07-16
MA39172B1 (fr) 2018-10-31
US10590118B2 (en) 2020-03-17
BR112016015311B1 (pt) 2023-01-24
JP2017502057A (ja) 2017-01-19
PL3092227T3 (pl) 2018-12-31
KR20160106164A (ko) 2016-09-09
NZ721993A (en) 2021-05-28
ES2687497T3 (es) 2018-10-25
US20160368906A1 (en) 2016-12-22
SA516371448B1 (ar) 2018-10-15
AU2015205339A1 (en) 2016-07-07
MY190835A (en) 2022-05-12
MX2016009052A (es) 2016-09-09
EP3092227B1 (fr) 2018-07-11

Similar Documents

Publication Publication Date Title
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
EA201892147A1 (ru) Бициклические соединения
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201590534A1 (ru) Новые бициклические производные
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
EA201300730A1 (ru) Производные индазолилтриазола
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
EA201790418A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
EA201490846A1 (ru) Новые производные арилхинолина
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
EA201270253A1 (ru) Производные n1-ацил-5-фторпиримидинона